Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Killer Cell Lectin-like Receptor Subfamily C Member 1 (NKG2A)
- Target
- NKG2A
- Molecular classification
- Receptor, Type II transmembrane protein, C-type lectin domain containing receptor, Immune checkpoint receptor
01
Overview
NKG2A is an inhibitory immune checkpoint receptor expressed on NK cells and CD8+ T cells. It forms a heterodimer with CD94 and binds to HLA-E, a non-classical MHC class I molecule. This interaction delivers inhibitory signals, preventing the activation of cytotoxic lymphocytes. Blocking this interaction enhances anti-tumor immunity and is a target for cancer immunotherapy.
- Other names
- NKG2-ACD159aKLRC1
02
Mechanism of action
NKG2A antagonists block the interaction between NKG2A and HLA-E, thereby restoring the cytotoxic activity of NK and CD8+ T cells.
03
Biological functions
Immune regulationInhibition of NK cell cytotoxicityInhibition of T cell cytotoxicitySelf-nonself discriminationInnate immunity
04
Disease associations
CancerViral infectionsAutoimmune diseasesInflammatory conditionsParasite infectionsTransplant rejectionColitisCeliac diseaseArthritis
05
Safety considerations
Potential for immune-related adverse events (irAEs)Risk of autoimmunityCytokine release syndrome
06
Interacting drugs
Monalizumab
07
Biomarkers
HLA-E expression level on tumor cellsNKG2A expression level on immune cells
Beyond the preview
Go deeper on Killer Cell Lectin-like Receptor Subfamily C Member 1 (NKG2A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Killer Cell Lectin-like Receptor Subfamily C Member 1 (NKG2A).